GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Omnicell Inc (NAS:OMCL) » Definitions » 10-Year RORE %

Omnicell (Omnicell) 10-Year RORE % : -19.35% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Omnicell 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Omnicell's 10-Year RORE % for the quarter that ended in Dec. 2023 was -19.35%.

The industry rank for Omnicell's 10-Year RORE % or its related term are showing as below:

OMCL's 10-Year RORE % is ranked worse than
80.42% of 286 companies
in the Healthcare Providers & Services industry
Industry Median: 7.095 vs OMCL: -19.35

Omnicell 10-Year RORE % Historical Data

The historical data trend for Omnicell's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omnicell 10-Year RORE % Chart

Omnicell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.44 6.18 14.19 -7.37 -19.35

Omnicell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.37 -15.61 -18.02 -21.62 -19.35

Competitive Comparison of Omnicell's 10-Year RORE %

For the Health Information Services subindustry, Omnicell's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omnicell's 10-Year RORE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Omnicell's 10-Year RORE % falls into.



Omnicell 10-Year RORE % Calculation

Omnicell's 10-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.45-0.83 )/( 6.614-0 )
=-1.28/6.614
=-19.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 10-year before.


Omnicell  (NAS:OMCL) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Omnicell 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Omnicell's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Omnicell (Omnicell) Business Description

Traded in Other Exchanges
Address
2625 Augustine Drive, Suite 301, Santa Clara, CA, USA, 95054
Omnicell Inc provides automation and business analytics software for healthcare providers. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.
Executives
Kaushik Ghoshal director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Christine Marie Mellon officer: EVP, Chief People Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Randall A Lipps director, officer: President and CEO 1101 EAST MEADOW DR, PALO ALTO CA 94303
Nchacha Etta officer: EVP & CFO 4220 NORTH FREEWAY, FORT WORTH TX 76137
Joanne B Bauer director 1400 HOLCOMB BRIDGE ROAD, ROSWELL GA 30076-2199
Scott Peter Seidelmann officer: EVP, Chief Commercial Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Peter J. Kuipers officer: Executive V.P. CFO 590 E. MIDDLEFEILD ROAD, MOUNTAIN VIEW CA 94043
Mary Garrett director ETHAN ALLEN DRIVE, DANBURY CT 06811
Manley Corey J officer: SR. VP & CHIEF LEGAL OFFICER 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Dan S Johnston officer: V.P., Legal & General Counsel
Joseph Brian Spears officer: Chief Accounting Officer & VP 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
James T Judson officer: VP Finance & Acting CFO C/O OMNICELL, INC., 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Robin Gene Seim officer: V.P., Finance & CFO 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Edward Peter Bousa director 280 CONGRESS STREET, BOSTON MA 02210
Nhat H Ngo officer: VP, Strategy & Business Dev. 490 NORTH WIGET LANE, WALNUT CREEK CA 94598

Omnicell (Omnicell) Headlines

From GuruFocus

Omnicell to Host Investor Day on September 20, 2022

By Business Wire Business Wire 08-25-2022

Omnicell Announces Leadership and Organizational Changes

By Business Wire Business Wire 05-30-2023

Omnicell to Present at the BofA Securities 2023 Healthcare Conference

By Business Wire Business Wire 05-03-2023

Insider Alert: An Insider Just Sold Omnicell Inc Shares

By GuruFocus Research GuruFocus Editor 12-20-2022